Tesofensine

Tesofensine
Clinical data
Pregnancy
category
  • Not applicable
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Bioavailability90%
Metabolism15–20% renal; hepatic: CYP3A4
Elimination half-life220 hours
ExcretionNot applicable
Identifiers
  • (1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H23Cl2NO
Molar mass328.28 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1Cl)[C@H]3C[C@H]2N(C)[C@H](CC2)[C@@H]3COCC
  • InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1 ☒N
  • Key:VCVWXKKWDOJNIT-ZOMKSWQUSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity.[1] Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.[2]

As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.[3]

  1. ^ Cite error: The named reference Doggrell was invoked but never defined (see the help page).
  2. ^ "NeuroSearch A/S signs agreement to transfer Phase I-II projects NS2359 and NS2330 (Tesofensine)". NeuroSearch company announcement. Retrieved 30 October 2014.
  3. ^ "Tesofensine - Saniona". AdisInsight. Springer Publishing. 29 January 2019. Retrieved 31 October 2019.